112 related articles for article (PubMed ID: 23758476)
1. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Awada Z; Haider S; Tfayli A; Bazarbachi A; El-Saghir NS; Salem Z; Shamseddine A; Taher A; Zgheib NK
OMICS; 2013 Jul; 17(7):353-67. PubMed ID: 23758476
[TBL] [Abstract][Full Text] [Related]
2. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
Nieuweboer AJ; Smid M; de Graan AM; Elbouazzaoui S; de Bruijn P; Eskens FA; Hamberg P; Martens JW; Sparreboom A; de Wit R; van Schaik RH; Mathijssen RH
Pharmacogenomics J; 2016 Nov; 16(6):519-524. PubMed ID: 26345519
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
Poirier E; Desbiens C; Poirier B; Hogue JC; Lemieux J; Doyle C; Leblond AF; Côté I; Cantin G; Provencher L
Ann Pharmacother; 2014 Apr; 48(4):447-55. PubMed ID: 24321851
[TBL] [Abstract][Full Text] [Related]
6. High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.
Callens C; Debled M; Delord M; Turbiez-Stalain I; Veyret C; Bièche I; Brain E
Breast Cancer Res Treat; 2015 Sep; 153(2):383-9. PubMed ID: 26318989
[TBL] [Abstract][Full Text] [Related]
7. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Deeken JF; Cormier T; Price DK; Sissung TM; Steinberg SM; Tran K; Liewehr DJ; Dahut WL; Miao X; Figg WD
Pharmacogenomics J; 2010 Jun; 10(3):191-9. PubMed ID: 20038957
[TBL] [Abstract][Full Text] [Related]
8. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Servitja S; Ramos M; Gil M; Sánchez-Rovira P; Vázquez-Estevez S; Virizuela JA; García-Estevez L; Velasco A; Tusquets I
Anticancer Drugs; 2012 Feb; 23(2):239-46. PubMed ID: 22112931
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
[TBL] [Abstract][Full Text] [Related]
13. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
19. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
Tham LS; Holford NH; Hor SY; Tan T; Wang L; Lim RC; Lee HS; Lee SC; Goh BC
Clin Cancer Res; 2007 Dec; 13(23):7126-32. PubMed ID: 18056193
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Longo R; D'Andrea M; Sarmiento R; Gasparini G
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S41-50. PubMed ID: 20374029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
